FindTrial
Sign In

Rivaroxaban 2.5 Mg Oral Tablet

DRUG9 trials

Sponsors

The George Institute, LifeBridge Health, Radboud University Medical Center, Mazandaran University of Medical Sciences, Science Valley Research Institute

Conditions

Acute Coronary SyndromeCardiovascular DiseaseChronic Kidney DiseasesCoronary Artery DiseaseDialysis-dependent Kidney FailureIntermittent ClaudicationIschemic StrokePeripheral Arterial Disease

Phase 2

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
CompletedNCT04273516
Mazandaran University of Medical SciencesPrevention, Stroke
Start: 2020-08-22End: 2023-04-30Updated: 2023-10-19

Phase 3

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
CompletedNCT03969953
The George InstituteCardiovascular Disease, Chronic Kidney Diseases, Dialysis-dependent Kidney Failure
Start: 2021-01-18End: 2025-10-30Updated: 2026-03-23

Phase 4

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy
NCT04059679
LifeBridge HealthCoronary Artery Disease, Peripheral Artery Disease
Start: 2020-01-30End: 2021-08-31Target: 30Updated: 2020-10-14
DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
CompletedNCT04218656
Radboud University Medical CenterPeripheral Artery Disease
Start: 2020-06-08End: 2021-12-31Updated: 2022-01-14
Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients
CompletedNCT04853719
Science Valley Research InstituteIntermittent Claudication, Peripheral Artery Disease
Start: 2021-04-20End: 2022-11-01Updated: 2024-08-06
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
CompletedNCT05009862
Vanderbilt University Medical CenterPeripheral Arterial Disease
Start: 2022-04-19End: 2025-07-01Updated: 2026-03-27
Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease
NCT05210725
Radboud University Medical CenterCoronary Artery Disease
Start: 2022-03-01End: 2022-07-01Updated: 2022-04-20
To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
NCT05573958
Sarmad ZahoorAcute Coronary Syndrome
Start: 2022-10-01End: 2023-07-31Target: 90Updated: 2022-10-10
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Not yet recruitingNCT06396858
Brazilian Clinical Research InstituteIschemic Stroke
Start: 2026-07-01End: 2027-12-01Target: 4500Updated: 2026-02-11

Related Papers

Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial
American Journal of Nephrology2026-02-09
Rivaroxaban for Patients with Intermittent Claudication
NEJM Evidence2024-08-267 citations
Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease.
2023-12-062 citations
Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial
Frontiers in Cardiovascular Medicine2022-10-063 citations
A protocol for DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease
Medicine Case Reports and Study Protocols2021-10-011 citations
Synergistic Influence of Rivaroxaban On Inflammation and Coagulation Biomarkers in Patients With Coronary Artery Disease and Peripheral Artery Disease On Aspirin Therapy
Future Cardiology2020-03-015 citations